UPDATED May 30, 2024
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
A119610 | ₩24,900.00 | 0% | -28.3% | ₩311.5b | ₩43,250.00 | PE22.6x | E48.0% | 2.4% | Healthcare | ||
688678 | CN¥16.48 | 0.9% | -11.4% | CN¥2.8b | CN¥27.00 | PE26.2x | E50.5% | 1.8% | Capital Goods | ||
5UH | €36.80 | -1.3% | 23.4% | €4.3b | €38.36 | PE72x | E42.5% | 1.1% | Capital Goods | ||
GBT | €36.65 | -1.2% | 115.1% | €461.0m | €39.47 | PE19.3x | E23.6% | 1.4% | Healthcare | ||
PIOC | PK₨159.09 | -1.4% | 81.1% | PK₨35.7b | PK₨142.50 | PE9.7x | E50.3% | 6.3% | Materials | ||
600388 | CN¥12.19 | 0.3% | -28.1% | CN¥13.1b | CN¥17.43 | PE25.1x | E34.4% | 1.6% | Capital Goods | ||
TSU | CA$40.25 | -1.7% | 12.7% | CA$1.9b | CA$58.11 | PE21.4x | E31.6% | n/a | Insurance | ||
300040 | CN¥6.74 | 1.5% | 7.7% | CN¥3.9b | n/a | PE46.9x | E63.8% | 1.0% | Capital Goods | ||
605108 | CN¥24.56 | -4.4% | -25.3% | CN¥6.4b | CN¥34.95 | PE21.4x | E24.7% | 1.7% | Consumer Services | ||
688278 | CN¥54.65 | 0.09% | 24.7% | CN¥22.2b | CN¥86.10 | PE37x | E30.8% | 0.8% | Pharmaceuticals & Biotech | ||
1651 | HK$10.28 | 0% | 24.6% | HK$3.9b | HK$10.23 | PE7.2x | E15.4% | 7.6% | Capital Goods | ||
600691 | CN¥2.15 | -3.6% | -31.1% | CN¥5.1b | n/a | PB1.1x | E108.6% | n/a | Materials | ||
300777 | CN¥25.33 | 1.0% | -47.2% | CN¥11.1b | CN¥30.31 | PE55.7x | E29.3% | 0.5% | Materials | ||
TPFG | UK£4.05 | 2.5% | 30.6% | UK£252.4m | UK£4.96 | PE34.1x | E36.7% | 3.0% | Real Estate Management and Development | ||
MUSTI | €25.60 | 0.6% | 33.0% | €854.7m | €24.00 | PE54.8x | E38.5% | 2.3% | Retail | ||
3587 | NT$277.00 | 2.6% | 22.6% | NT$18.2b | NT$305.00 | PE27x | E27.9% | 2.9% | Semiconductors | ||
AZT | kr24.10 | -7.1% | -41.1% | kr1.2b | kr27.50 | PE69.8x | E48.5% | n/a | Pharmaceuticals & Biotech | ||
300201 | CN¥3.86 | -0.3% | 8.4% | CN¥3.8b | n/a | PE18.5x | E22.1% | 0.9% | Capital Goods | ||
HBIO | US$3.12 | -1.3% | -45.5% | US$135.5m | US$7.00 | PS1.3x | E106.7% | n/a | Pharmaceuticals & Biotech | ||
AKVA | kr63.80 | -1.5% | 3.2% | kr2.3b | kr65.00 | PB2x | E76.7% | 0% | Capital Goods | ||
2324 | CN¥10.18 | 4.5% | -31.0% | CN¥11.2b | CN¥11.80 | PE25.3x | E29.9% | 0.5% | Materials | ||
SMAR | US$37.09 | -6.5% | -23.7% | US$5.1b | US$49.26 | PS5.3x | E50.5% | n/a | Software | ||
300873 | CN¥16.39 | 6.4% | -24.2% | CN¥3.7b | CN¥25.10 | PE13.4x | E29.2% | 2.4% | Transportation | ||
ENFN | US$9.38 | -0.1% | 15.9% | US$1.2b | US$9.82 | PE429.1x | E99.0% | n/a | Software |